Rapid Therapeutic Science Laboratories, Inc. (RTSL) Cash from Investing Activities (2019 - 2022)

Rapid Therapeutic Science Laboratories' Cash from Investing Activities history spans 4 years, with the latest figure at $315646.0 for Q4 2022.

  • For Q4 2022, Cash from Investing Activities rose 280.0% year-over-year to $315646.0; the TTM value through Jun 2023 reached $315645.0, up 151.95%, while the annual FY2022 figure was -$39155.0, 86.62% up from the prior year.
  • Cash from Investing Activities for Q4 2022 was $315646.0 at Rapid Therapeutic Science Laboratories, up from -$1.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $315646.0 in Q4 2022 and bottomed at -$319596.0 in Q2 2022.
  • The 4-year median for Cash from Investing Activities is -$56298.5 (2021), against an average of -$56981.6.
  • The largest YoY upside for Cash from Investing Activities was 280.0% in 2022 against a maximum downside of 1497.98% in 2022.
  • A 4-year view of Cash from Investing Activities shows it stood at -$145151.0 in 2019, then skyrocketed by 35.94% to -$92979.0 in 2020, then plummeted by 88.6% to -$175359.0 in 2021, then skyrocketed by 280.0% to $315646.0 in 2022.
  • Per Business Quant, the three most recent readings for RTSL's Cash from Investing Activities are $315646.0 (Q4 2022), -$1.0 (Q3 2022), and -$319596.0 (Q2 2022).